P0F Stock Chart & Stats
$0.58
$0.03(6.17%)
―
--
Day’s Range― - ―
52-Week Range$0.36 - $0.67
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
€254.38M
Enterprise Value$2.11K
Total Cash (Recent Filing)€142.50M
Total Debt (Recent Filing)€75.20M
Price to Earnings (P/E)―
Beta-0.70
Next Earnings
Aug 21, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding464,947,240
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.10Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)€36.11M
Bulls Say, Bears Say
Bulls Say
Orphan / Rare-disease FocusA clear strategic focus on orphan and rare indications provides durable advantages: smaller, more predictable patient populations, potential for accelerated regulatory pathways, pricing and exclusivity benefits, and a differentiated commercial niche that can sustain margins and licensing opportunities long-term.
Strong Recent Revenue GrowthSustained double-digit revenue expansion (TTM +112%) signals improving commercial traction or milestone receipts that can validate programs and support scale. If maintained, this trend underpins reinvestment capacity and reduces binary program risk versus companies with flat or declining top lines.
Manageable Reported LeverageA modest debt-to-equity ratio (~0.30) provides structural financial flexibility and lowers near-term solvency risk versus highly leveraged peers. This makes refinancing or targeted borrowing for milestone-driven development less risky and preserves optionality for strategic partnerships or licensing.
Bears Say
Severe Negative Cash Flow And Worsening BurnDeep, persistent negative operating and free cash flow (~-265M TTM) is a structural weakness: it shortens runway, forces recurrent financing, elevates dilution risk, and can constrain ability to fund trials or commercialization without external capital, impairing long-term strategic execution.
Large Persistent Operating And Net LossesOperating and net losses far exceed revenue, producing an extreme negative margin profile (~-592%). This indicates the company is not close to profitability; sustained losses weaken reinvestment capacity, depress returns metrics, and require continued capital raising to sustain development programs.
Capital Erosion And Sharply Negative ROEMaterial decline in equity and ROE near -98% reflect capital erosion from sustained losses. This reduces balance-sheet resilience, limits strategic flexibility, increases the likelihood of equity dilution, and makes the company more dependent on external financing for future milestones.
Egetis Therapeutics AB News
P0F FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was $0.36 and its highest was $0.67 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is €254.38M.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 14 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Apr 29, 2026. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of -$0.017 by -$0.005.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.01.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -$0.022 in its last earnings report, missing expectations of -$0.017. Following the earnings report the stock price went down -2.33%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in DE:P0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
P0F Stock 12 Month Forecast
Average Price Target
$2.10